In short
Clinical trials are studying AP31969 SULFATE in people with atrial fibrillation. These trials aim to see how well it works for rhythm control and to measure safety and other research outcomes. The main study is a phase 2 trial comparing AP31969 SULFATE with placebo in adults with atrial fibrillation.
Key points
- AP31969 SULFATE is being studied in a phase 2 clinical trial for atrial fibrillation, a heart rhythm problem. The trial compares AP31969 SULFATE with placebo to see whether it can reduce AF burden. The study is interventional and plans to enroll 200 people. The main outcome is AF burden from week 2 to week 12. The available trial data focus on rhythm control in adults with atrial fibrillation.
Trial overview
The available trial data describe one randomised Phase 2 study of AP31969 SULFATE for rhythm control in atrial fibrillation. The study is interventional, which means researchers give a study treatment and compare outcomes between groups.
The trial is authorised and is designed to assess the effect of AP31969 SULFATE on atrial fibrillation burden. Atrial fibrillation is the condition being studied in this trial.
Who is being studied
The target population is people with atrial fibrillation. The source data do not give more detail about age limits, symptom requirements, or other entry rules.
Because this is a trial for rhythm control, the study is focused on people whose heart rhythm problem may be measured over time. The trial data do not list any subgroup such as newly diagnosed patients or patients with a certain type of atrial fibrillation.
Treatment groups and study design
The study compares AP31969 SULFATE with placebo. A placebo is a tablet that looks the same as the active study drug but does not contain AP31969 SULFATE.
The source data list several oral AP31969 SULFATE tablet strengths: 200 mg, 400 mg, 700 mg, and 1000 mg. The placebo tablets are described as visually identical to the active tablets, which helps keep the comparison fair.
This design helps researchers compare outcomes between people receiving AP31969 SULFATE and people receiving placebo. The trial brief summary says the goal is to assess the effect of AP31969 SULFATE on atrial fibrillation burden.
Study phase and size
This is a Phase 2 trial. Phase 2 studies usually look more closely at whether a treatment may work while continuing to gather safety information, but the source data only directly confirm the phase and study goal.
The planned enrollment is 200 people. Enrollment means the number of participants the researchers plan to include in the study.
What the trial measures
The primary outcome is AF burden from week 2 to week 12. Primary outcome means the main result the researchers want to measure.
AF burden means how much atrial fibrillation a person has during the study period. By measuring this over time, the trial can show whether AP31969 SULFATE changes the amount of rhythm problem compared with placebo.
What the data does not say
The source data do not list secondary outcomes, detailed eligibility rules, or follow-up beyond week 12.
The source data also do not provide results yet, so this trial description is about the study plan rather than the final findings.